Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Merck Will Study Cancidas/Antifungal Combinations In Phase IV Trials

Executive Summary

Merck will study Cancidas in combination with other antifungals for invasive aspergillosis treatment.

You may also be interested in...



Merck Sterile Product Manufacturing Difficulties Affect Cancidas, Timoptic

Merck's recently launched antifungal Cancidas is in short supply as a result of manufacturing difficulties affecting the company's sterile product lines

Merck Sterile Product Manufacturing Difficulties Affect Cancidas, Timoptic

Merck's recently launched antifungal Cancidas is in short supply as a result of manufacturing difficulties affecting the company's sterile product lines

Merck Cancidas Label Should Highlight Cyclosporine Data - FDA Committee

Labeling for Merck's antifungal Cancidas should include all available data on concomitant use with cyclosporine, although coadministration of the products is not recommended, FDA's Antiviral Drug Products Advisory Committee said Jan. 10.

Related Content

UsernamePublicRestriction

Register

PS037299

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel